A Dutch news item reports developments in RSV research. Julius Clinical Associated Scientist and ReSViNET Chairman Louis Bont comments ‘ there is light at the horizon, but we haven't reached it yet.’ The study outcome with administering GS-5806 in RSV-infected adults has shown promise, but dr. Bont does not expect the result to hold in a placebo-controlled trial in RSV infected children.
When RSV-infected children are admitted to the hospital, their viral load is most likely too high in order for GS-5806 to be effective. Next to that, the body's defense mechanism’s response to the virus can also harm the lungs of the patient, next to the harmful effects of the virus itself. This mechanism has not been addressed in this study, therefore practical application of the compound is questionable.
It is, however, a step in the direction of a cure. The Dutch article can be read here.